LB Pharmaceuticals (LBRX) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and pipeline

• Aims to build a fully integrated neuropsychiatric company, leveraging LB-102, a late-stage asset derived from a validated antipsychotic with 40 years of clinical use.

• LB-102 is positioned as the first benzamide antipsychotic in the U.S., with a long-acting injectable formulation in development and multiple clinical milestones expected through Q2 2029.

• Strong intellectual property and financial runway support ongoing and future clinical trials across schizophrenia, bipolar depression, and major depressive disorder (MDD).

Clinical development and trial results

• Positive phase II data in schizophrenia showed statistically significant and clinically meaningful improvements in PANSS scores at all tested doses, with robust control of placebo rates.

• Cognitive improvements were dose-dependent and among the highest observed in acute schizophrenia studies, with plans to evaluate cognition in all future trials.

• Adverse events were mild to moderate, with low rates of extrapyramidal symptoms (EPS), minimal sedation, and low discontinuation rates, supporting a favorable safety profile.

• Ongoing phase III trial in schizophrenia mirrors phase II design, with results expected in H2 2027, alongside a 900-patient open-label safety study.

Expansion into mood disorders

• LB-102’s mechanism supports expansion into bipolar depression and adjunctive MDD, targeting residual symptoms like anhedonia and cognitive deficits, which are not well addressed by current therapies.

• Bipolar depression phase II trial began in early 2024, with top-line data expected Q1 2028; adjunctive MDD trial to start in early 2027, with results in H1 2029.

• Both trials use a fixed flexible dose design to optimize efficacy and minimize placebo rates, with the MDD trial conducted in both the U.S. and Europe.